My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

4.287 +0.147 (+3.54%)

Streaming Delayed Price Updated: 11:15 AM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

August 17, 2023

WHY: NEW YORK, NY - (NewMediaWire) - August 17, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17,...

Via NewMediaWire

Topics Lawsuit

NASDAQ: ALDX Investor Alert: Lawsuit Alleges Misleading Statements by Aldeyra Therapeutics, Inc. ↗

August 17, 2023

San Diego, CA -- (SBWIRE) -- 08/17/2023 -- An investor, who purchased shares of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), filed a lawsuit over alleged violations of Federal Securities Laws by Aldeyra...

Via SBWire

Topics Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lordstown, AT&T, and Aldeyra and Encourages Investors to Contact the Firm

August 16, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALDX

August 16, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

Expert Ratings for Aldeyra Therapeutics ↗

August 09, 2023

Via Benzinga

ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

August 14, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ROSEN, LEADING INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

August 14, 2023

WHY: New York, NY - (NewMediaWire) - August 13, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17,...

Via TheNewswire.com

Topics Lawsuit

ROSEN, LEADING INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

August 13, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

August 12, 2023

WHY: New York, NY - (NewMediaWire) - August 12, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17,...

Via TheNewswire.com

Topics Lawsuit

ROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

August 12, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lordstown, AT&T, Aldeyra, and RTX and Encourages Investors to Contact the Firm

August 11, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)

August 11, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)

August 10, 2023

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Aldeyra Therapeutics, Inc. (ALDX) Investors

August 09, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

Aldeyra Therapeutics, Inc. (ALDX) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Aldeyra Therapeutics, Inc. Securities Class Action

August 08, 2023

From Robbins LLP

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Aldeyra Therapeutics, Inc. (ALDX) Investors

August 08, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

ROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

August 08, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ALDEYRA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm

August 08, 2023

From Bragar Eagel & Squire, P.C.,

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aldeyra Therapeutics, Inc. (ALDX) Investors

August 07, 2023

From Law Offices of Howard G. Smith

Via Business Wire

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

August 06, 2023

Via ACCESSWIRE

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

August 04, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

August 03, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

August 03, 2023

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

August 03, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALDX

August 02, 2023

From Rosen Law Firm

Via Business Wire

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Aldeyra Therapeutics, Inc. (ALDX)

August 01, 2023

From Robbins LLP

Via Business Wire

Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum

July 06, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa

June 29, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa

June 28, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo ↗

June 27, 2023

Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced top-line results from the Phase 2 clinical trial of ADX‑629, an investigational new drug administered orally to

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.